CA2998902C - Composes macrocycliques comme inhibiteurs du facteur xia - Google Patents

Composes macrocycliques comme inhibiteurs du facteur xia Download PDF

Info

Publication number
CA2998902C
CA2998902C CA2998902A CA2998902A CA2998902C CA 2998902 C CA2998902 C CA 2998902C CA 2998902 A CA2998902 A CA 2998902A CA 2998902 A CA2998902 A CA 2998902A CA 2998902 C CA2998902 C CA 2998902C
Authority
CA
Canada
Prior art keywords
mmol
alkyl
mixture
stirred
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2998902A
Other languages
English (en)
Other versions
CA2998902A1 (fr
Inventor
Jiayi Xu
Amjad Ali
Wei Zhou
Ying-Duo Gao
Scott D. Edmondson
Eric Mertz
Santhosh F. NEELAMKAVIL
Weiguo Liu
Wanying Sun
Dong-Ming Shen
Bart Harper
Cheng Zhu
Thomas Bara
Yeon-Hee Lim
Meng Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of CA2998902A1 publication Critical patent/CA2998902A1/fr
Application granted granted Critical
Publication of CA2998902C publication Critical patent/CA2998902C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La présente invention concerne un composé de formule (I) et des compositions pharmaceutiques comprenant un ou plusieurs desdits composés, ainsi que des méthodes d'utilisation desdits composés pour traiter ou prévenir les thromboses, les embolies, l'hypercoagulabilité ou les modifications fibrotiques. Lesdits composés sont des inhibiteurs sélectifs du facteur XIa ou des inhibiteurs doubles du facteur XIa et de kallicréine plasmatique.
CA2998902A 2015-10-29 2016-10-24 Composes macrocycliques comme inhibiteurs du facteur xia Active CA2998902C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562248075P 2015-10-29 2015-10-29
US62/248,075 2015-10-29
PCT/US2016/058362 WO2017074832A1 (fr) 2015-10-29 2016-10-24 Inhibiteurs du facteur xia

Publications (2)

Publication Number Publication Date
CA2998902A1 CA2998902A1 (fr) 2017-05-04
CA2998902C true CA2998902C (fr) 2024-03-26

Family

ID=58631804

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2998902A Active CA2998902C (fr) 2015-10-29 2016-10-24 Composes macrocycliques comme inhibiteurs du facteur xia

Country Status (12)

Country Link
US (1) US10214512B2 (fr)
EP (1) EP3368036B1 (fr)
JP (1) JP6892858B2 (fr)
KR (1) KR102727485B1 (fr)
CN (1) CN108430471B (fr)
AU (1) AU2016344476B2 (fr)
BR (1) BR112018008506B8 (fr)
CA (1) CA2998902C (fr)
MA (1) MA43128A (fr)
MX (1) MX387515B (fr)
RU (1) RU2728783C2 (fr)
WO (1) WO2017074832A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3870171B1 (fr) 2018-10-25 2024-11-20 Merck Sharp & Dohme LLC Inhibiteurs du facteurs xia
CN113015730A (zh) * 2018-11-13 2021-06-22 诺华股份有限公司 用于治疗与nlrp活性相关的病症的化合物和组合物
WO2020211781A1 (fr) 2019-04-16 2020-10-22 南京明德新药研发有限公司 Dérivés macrocycliques agissant comme inhibiteur du facteur xia
CN114008047B (zh) 2019-07-23 2023-03-21 南京明德新药研发有限公司 作为XIa因子抑制剂的大环衍生物
KR20230038526A (ko) 2020-07-10 2023-03-20 머크 샤프 앤드 돔 엘엘씨 혈장 칼리크레인 억제제
CA3206548A1 (fr) 2021-01-28 2022-08-04 John S. Debenham Inhibiteurs du facteur xia
US11814364B2 (en) 2021-03-18 2023-11-14 Janssen Pharmaceutica Nv Pyridine N-oxide derivatives useful as factor XIa inhibitors
US11919881B2 (en) 2021-03-18 2024-03-05 Janssen Pharmaceutica Nv Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11845748B2 (en) 2021-03-18 2023-12-19 Janssen Pharmaceutica Nv Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2426716A1 (fr) 2000-11-07 2002-05-16 Gregory S. Bisacchi Derives d'acides utilises comme inhibiteurs de la serine protease
EP1332131A2 (fr) 2000-11-07 2003-08-06 Bristol-Myers Squibb Company Derives d'acide utiles comme inhibiteurs de serines proteases
JP2004518688A (ja) 2001-01-30 2004-06-24 ブリストル−マイヤーズ　スクイブ　カンパニー ファクターＸａ阻害剤のスルホンアミドラクタムおよびその方法
WO2003015715A2 (fr) 2001-08-20 2003-02-27 Bristol-Myers Squibb Company Derives de tetrahydroquinoline utilises comme agents antithrombotiques
WO2004002405A2 (fr) 2002-06-26 2004-01-08 Bristol-Myers Squibb Company Pyrazinones amino-bicycliques et pyridinones utilisees comme inhibiteurs de coagulation de la serine protease
US20040180855A1 (en) 2003-02-19 2004-09-16 Schumacher William A. Methods of treating thrombosis with reduced risk of increased bleeding times
US7138412B2 (en) 2003-03-11 2006-11-21 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives useful as serine protease inhibitors
US7129264B2 (en) 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
US7417063B2 (en) 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
US20060074103A1 (en) 2004-10-06 2006-04-06 Corte James R Cyclic beta-amino acid derivatives as factor Xa inhibitors
EP1828152B1 (fr) 2004-12-08 2008-08-20 Bristol-Myers Squibb Company Composes heterocycliques utilises comme inhibiteurs du facteur viia
DE602006016566D1 (de) 2005-01-10 2010-10-14 Bristol Myers Squibb Co Als antikoagulanzien verwendbare phenylglycinamid-derivate
EP1841504B1 (fr) 2005-01-13 2014-11-19 Bristol-Myers Squibb Company Composés de biaryle substitués en tant qu'inhibiteurs du facteur xia
US20060183771A1 (en) 2005-02-17 2006-08-17 Seiffert Dietmar A Novel combination of selective factor VIIa and/or factor XIa inhibitors and selective plasma kallikrein inhibitors
BRPI0610506A2 (pt) * 2005-04-20 2010-06-29 Johnson & Johnson moduladores de trombina de n-óxidos de piridina fluorados e processo para n-oxidação de heteroarilas contendo nitrogênio
WO2007070816A2 (fr) 2005-12-14 2007-06-21 Bristol-Myers Squibb Company Derives de thiophene en tant qu'inhibiteurs du facteur xia
EP1966141A1 (fr) 2005-12-14 2008-09-10 Brystol-Myers Squibb Company Heterocycles a six elements utiles en tant qu inhibiteurs de serine protease
NZ568595A (en) 2005-12-14 2010-04-30 Bristol Myers Squibb Co Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor Xla inhibitors
WO2007109459A2 (fr) 2006-03-21 2007-09-27 Janssen Pharmaceutica, Nv Pyridines et n-oxydes de pyridine en tant que modulateurs de la thrombine
EP2102189B1 (fr) 2006-12-15 2015-07-29 Bristol-Myers Squibb Company Analogues d'arylpropionamide, d'arylacrylamide, d'arylpropynamide ou d'arylméthylurée en tant qu'inhibiteurs du facteur xia
CN101784516B (zh) * 2007-06-13 2014-07-02 百时美施贵宝公司 作为凝血因子抑制剂的二肽类似物
US8324199B2 (en) 2008-03-13 2012-12-04 Bristol-Myers Squibb Company Pyridazine derivatives as factor xia inhibitors
NZ602266A (en) 2010-02-11 2014-05-30 Bristol Myers Squibb Co Macrocycles as factor xia inhibitors
TW201319068A (zh) * 2011-08-05 2013-05-16 必治妥美雅史谷比公司 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑
TW201311689A (zh) 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子ｘｉａ抑制劑之新穎巨環化合物
EP2766347B1 (fr) 2011-10-14 2016-05-04 Bristol-Myers Squibb Company Composés de tétrahydroisoquinoléine substitués en tant qu'inhibiteurs du facteur xia
WO2013055984A1 (fr) 2011-10-14 2013-04-18 Bristol-Myers Squibb Company Composés tétrahydroisoquinolines substitués en tant qu'inhibiteurs du facteur xia
JP6033319B2 (ja) 2011-10-14 2016-11-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 第ＸＩａ因子阻害剤としての置換テトラヒドロイソキノリン化合物
US9732085B2 (en) 2011-12-21 2017-08-15 Ono Pharmaceutical Co., Ltd. Pyridinone and pyrimidinone derivatives as factor Xia
JP2015083542A (ja) 2012-02-08 2015-04-30 大日本住友製薬株式会社 ３位置換プロリン誘導体
US9376444B2 (en) * 2012-08-03 2016-06-28 Bristol-Myers Squibb Company Dihydropyridone P1 as factor XIa inhibitors
AU2013296259A1 (en) * 2012-08-03 2015-03-19 Bristol-Myers Squibb Company Dihydropyridone P1 as factor XIa inhibitors
WO2014160592A2 (fr) 2013-03-27 2014-10-02 Merck Sharp & Dohme Corp. Inhibiteurs du facteur xia
SG10201908467RA (en) * 2014-01-31 2019-10-30 Bristol Myers Squibb Co Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
NO2760821T3 (fr) * 2014-01-31 2018-03-10
US9663527B2 (en) * 2014-02-11 2017-05-30 Merck Sharp & Dohme Corp. Factor XIa inhibitors
US9555031B2 (en) * 2014-04-11 2017-01-31 The University Of North Carolina At Chapel Hill Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity
US9453018B2 (en) * 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
US20180162821A1 (en) * 2016-12-14 2018-06-14 Bristol-Myers Squibb Company Factor xia macrocycles with novel p1 groups

Also Published As

Publication number Publication date
CN108430471B (zh) 2021-07-09
CA2998902A1 (fr) 2017-05-04
BR112018008506A2 (pt) 2018-10-23
AU2016344476A1 (en) 2018-03-08
BR112018008506B8 (pt) 2023-12-05
JP2018531954A (ja) 2018-11-01
MX387515B (es) 2025-03-18
US20180339977A1 (en) 2018-11-29
KR20180073602A (ko) 2018-07-02
JP6892858B2 (ja) 2021-06-23
RU2018119015A3 (fr) 2020-02-18
EP3368036A4 (fr) 2019-04-17
BR112018008506B1 (pt) 2023-11-14
MA43128A (fr) 2018-09-05
KR102727485B1 (ko) 2024-11-06
MX2018005045A (es) 2018-08-01
AU2016344476B2 (en) 2020-08-13
CN108430471A (zh) 2018-08-21
EP3368036A1 (fr) 2018-09-05
EP3368036B1 (fr) 2022-07-20
RU2018119015A (ru) 2019-11-29
WO2017074832A1 (fr) 2017-05-04
RU2728783C2 (ru) 2020-07-31
US10214512B2 (en) 2019-02-26

Similar Documents

Publication Publication Date Title
CA2998902C (fr) Composes macrocycliques comme inhibiteurs du facteur xia
EP3134408B1 (fr) Inhibiteurs du facteur xia
EP3180327B1 (fr) Inhibiteurs du facteur xia
EP3283464B1 (fr) Inhibiteurs de facteur xia
EP3180317B1 (fr) Inhibiteurs du facteur xia
EP3148542A1 (fr) Inhibiteurs du facteur xia
AU2016209623B2 (en) Factor XIa inhibitors
EP3383847B1 (fr) Inhibiteurs du facteur xia
US9975874B2 (en) Factor XIa inhibitors
CN116157154A (zh) 血浆激肽释放酶抑制剂

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210913

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250908

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250908